Neurocrine Biosciences (NASDAQ:NBIX) has been given a $110.00 price target by equities research analysts at Oppenheimer in a report issued on Tuesday. The firm currently has a “buy” rating on the stock. Oppenheimer’s price target points to a potential upside of 19.18% from the company’s previous close.
NBIX has been the subject of a number of other research reports. Jefferies Group boosted their target price on Neurocrine Biosciences to $105.00 and gave the stock a “buy” rating in a report on Friday, January 5th. JPMorgan Chase & Co. boosted their target price on Neurocrine Biosciences from $79.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, February 14th. Barclays reiterated an “overweight” rating and set a $100.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, February 14th. Needham & Company LLC reiterated a “buy” rating and set a $110.00 target price (up previously from $95.00) on shares of Neurocrine Biosciences in a report on Thursday, February 22nd. Finally, BidaskClub upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $95.23.
Shares of Neurocrine Biosciences (NBIX) opened at $92.30 on Tuesday. The company has a current ratio of 10.20, a quick ratio of 10.20 and a debt-to-equity ratio of 0.99. Neurocrine Biosciences has a fifty-two week low of $39.21 and a fifty-two week high of $92.98. The stock has a market capitalization of $8,240.00, a PE ratio of -56.63 and a beta of 0.30.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.11). The firm had revenue of $94.52 million during the quarter, compared to analyst estimates of $94.00 million. During the same period in the prior year, the firm earned ($0.51) EPS. research analysts expect that Neurocrine Biosciences will post -0.25 earnings per share for the current fiscal year.
In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 75,873 shares of the company’s stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $90.00, for a total value of $6,828,570.00. Following the transaction, the insider now directly owns 18,041 shares of the company’s stock, valued at approximately $1,623,690. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Darin Lippoldt sold 15,237 shares of the company’s stock in a transaction that occurred on Thursday, December 28th. The shares were sold at an average price of $75.00, for a total value of $1,142,775.00. Following the completion of the transaction, the insider now directly owns 28,394 shares in the company, valued at $2,129,550. The disclosure for this sale can be found here. In the last 90 days, insiders sold 399,589 shares of company stock valued at $32,443,795. 4.80% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in NBIX. Perceptive Advisors LLC raised its position in shares of Neurocrine Biosciences by 33.9% in the 3rd quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock valued at $293,629,000 after purchasing an additional 1,214,000 shares in the last quarter. American Century Companies Inc. raised its position in shares of Neurocrine Biosciences by 1,257.3% during the 4th quarter. American Century Companies Inc. now owns 490,648 shares of the company’s stock valued at $38,069,000 after acquiring an additional 454,500 shares in the last quarter. Millennium Management LLC raised its position in shares of Neurocrine Biosciences by 357.3% during the 4th quarter. Millennium Management LLC now owns 534,566 shares of the company’s stock valued at $41,477,000 after acquiring an additional 417,661 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at approximately $30,046,000. Finally, Allianz Asset Management GmbH raised its position in shares of Neurocrine Biosciences by 773.4% during the 4th quarter. Allianz Asset Management GmbH now owns 350,325 shares of the company’s stock valued at $27,182,000 after acquiring an additional 310,214 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: “Neurocrine Biosciences (NBIX) Given a $110.00 Price Target by Oppenheimer Analysts” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/03/15/neurocrine-biosciences-nbix-given-a-110-00-price-target-by-oppenheimer-analysts.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.